Mashimo K
Drugs. 1981;22 Suppl 1:100-7. doi: 10.2165/00003495-198100221-00021.
The biliary excretion of cefoperazone in experimental animals, and humans, was investigated. Biliary excretion of cefoperazone in rats, rabbits, dogs, and monkeys was always higher than that of cephazolin. Biliary excretion was markedly reduced in experimentally-produced liver cirrhosis in rats. Comparing the biliary excretion of cefoperazone and cephazolin in a crossover study in patients, the excretion of cefoperazone was shown to be much higher than that of cephazolin. In clinical studies in 116 patients with biliary tract infections such as cholecystitis, cholangitis, and liver abscess, cefoperazone was effective in 90 (78%). The incidence of side effects was low. In conclusion, cefoperazone was considered to be effective in treating biliary tract infections because of its broad antibacterial spectrum and high penetration into bile.
对头孢哌酮在实验动物和人体中的胆汁排泄情况进行了研究。头孢哌酮在大鼠、兔子、狗和猴子体内的胆汁排泄量始终高于头孢唑林。在实验性诱导的大鼠肝硬化模型中，胆汁排泄显著减少。在一项针对患者的交叉研究中比较头孢哌酮和头孢唑林的胆汁排泄情况，结果显示头孢哌酮的排泄量远高于头孢唑林。在116例患有胆囊炎、胆管炎和肝脓肿等胆道感染的患者的临床研究中，头孢哌酮对90例（78%）患者有效。副作用发生率较低。总之，由于头孢哌酮具有广谱抗菌活性和高胆汁渗透性，被认为对治疗胆道感染有效。
